Decision tool to help you choose radioactive iodine after intermediate-risk thyroid cancer
Use of a decision aid to resolve uncertainty about radioactive iodine treatment in patients with intermediate-risk thyroid cancer: the Radiance trial
['FUNDING_OTHER'] · GEORGETOWN UNIVERSITY · NIH-11294188
A patient-friendly decision aid will help people with intermediate-risk thyroid cancer weigh the benefits and risks of adding radioactive iodine after surgery.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGETOWN UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11294188 on ClinicalTrials.gov |
What this research studies
If you have intermediate-risk differentiated thyroid cancer and are deciding between surgery alone or surgery plus radioactive iodine (RAI), this project offers a clear decision aid to explain the possible benefits, side effects, and uncertainties. The team will build the tool using existing evidence and patient input, then offer it to patients who are facing this treatment choice. Researchers will track how the tool affects what patients choose, how confident they feel about their decision, and short-term quality-of-life outcomes.
Who could benefit from this research
Good fit: People diagnosed with intermediate-risk differentiated thyroid cancer who are deciding whether to receive radioactive iodine after surgery.
Not a fit: Patients for whom RAI is already clearly recommended (high-risk) or clearly not recommended (low-risk), or those not currently facing the RAI decision, are unlikely to benefit from this tool.
Why it matters
Potential benefit: If successful, the decision aid could reduce uncertainty, improve informed decision-making, and help avoid unnecessary RAI and its side effects.
How similar studies have performed: Decision aids have improved knowledge and reduced decisional conflict in other cancer treatment choices, but applying one specifically to RAI decisions in intermediate-risk thyroid cancer is relatively new.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGETOWN UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JONKLAAS, JACQUELINE — GEORGETOWN UNIVERSITY
- Study coordinator: JONKLAAS, JACQUELINE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: American Cancer Society, Cancer Patient, Cancer Survivor